SCHEDULE: J&J Reduces Stake in Rapport Therapeutics to 4.9%

Johnson & Johnson and its subsidiary JJDC have reduced their beneficial ownership in Rapport Therapeutics, Inc. to 4.9% of common stock.

Summary

• Johnson & Johnson (J&J) and its wholly-owned subsidiary, Johnson & Johnson Innovation JJDC, Inc. (JJDC), filed an Amendment No. 1 to Schedule 13G.
• The filing reports their beneficial ownership in Rapport Therapeutics, Inc. common stock.
• As of September 30, 2025, the reporting persons beneficially own 1,784,517 shares.
• This represents 4.9% of Rapport Therapeutics' common stock outstanding.
• The percentage ownership is based on 36,497,920 shares outstanding as of August 4, 2025, as reported in the Issuer's Form 10-Q for the period ended June 30, 2025.
• This amendment indicates a reduction in their stake, as the reported ownership is now below the 5% threshold typically requiring a Schedule 13G filing.

Sentiment

Score: 3

Explanation: The reduction of a significant institutional investor's stake below the 5% threshold is generally perceived as a negative development, potentially signaling a lack of confidence or a strategic shift by the investor. While not a catastrophic event, it removes a large, stable shareholder and could put downward pressure on the stock.

Negatives

• Johnson & Johnson, a significant institutional investor, has reduced its beneficial ownership in Rapport Therapeutics, Inc. to below 5%.
• The reduction of a major investor's stake can be perceived negatively by the market, potentially signaling a lack of confidence or a reallocation of capital.

Risks

• Potential negative market reaction due to a major institutional investor reducing its stake.
• Increased selling pressure on Rapport Therapeutics' stock if J&J continues to divest its remaining shares.

Future Outlook

NA

Industry Context

Schedule 13G filings are standard disclosures for passive investors holding 5% or more of a company's stock. An amendment indicating a reduction below this threshold signifies a change in investment strategy or portfolio rebalancing by a major institutional holder like Johnson & Johnson, which can be closely watched by the market, especially in the biotechnology and pharmaceutical sectors where strategic investments are common.

Stakeholder Impact

• Shareholders: May experience negative sentiment and potential downward pressure on stock price due to a major investor reducing its stake.
• Management: May face questions regarding the reasons for the divestment and its implications for future strategic partnerships or funding.

Key Dates

Recommendation

The reduction of Johnson & Johnson's stake in Rapport Therapeutics to below 5% signals a divestment by a significant institutional investor. This action, particularly by a strategic player like J&J, can be interpreted as a loss of confidence or a strategic re-prioritization. Such a move typically leads to negative market sentiment and potential selling pressure on the stock. Investors might consider selling to mitigate potential downside risk associated with this institutional exit.

Keywords

Rapport Therapeutics, Johnson & Johnson, JJDC, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Equity Stake, Pharmaceuticals, Biotechnology